Chronic exposure of pancreatic islets to sulfonylureas (SUs) is known to impair the ability of islets to respond to subsequent acute stimulation by SUs or glucose. Nateglinide (NAT) is a novel insulinotropic agent with a primarily site of action at /3-cell KATP channels, which is common to the structurally diverse drugs like repaglinide (REP) and the SUs. Earlier studies on the kinetics, glucosedependence and sensitivity to metabolic inhibitors of the interaction between NAT and KATP channels suggested a distinct signaling pathways with NAT compared to REP, glyburide (GLY) or glimepiride (GLI). To obtain further evidence for this concept, the present study compared the insulin secretion in vitro from rat islets stimulated acutely by NAT, GLY, GLI or REP at equipotent concentrations during 1-hr static incubation following overnight treatment with GLY or tolbutamide (TOL). The islets fully retained the responsiveness to NAT stimulation after prolonged pretreatment with both SUs, while their acute response to REP, GLY, and GLI was markedly attenuated, confirming the desensitization of islets. The insulinotropic efficacy of NAT in islets desensitized to SUs may result from a distinct receptor/effector mechanism, which contributes to the unique pharmacological profile of NAT.
INTRODUCTION
Sulfonylureas (SUs) are widely used in the treatment of non-insulin-dependent (Type 2) diabetes. They stimulate insulin secretion by closing ]-cell plasma membrane KAT p channels, [1] which are formed by the molecular interaction between a high-affinity SU receptor, SUR1 , and an inwardly rectifying K + channel subunit, Kir6.2. [2] The closure of KATP channels leads to the opening of voltage-dependent Ca 2 + channels, Ca 2 + influx and stimulation of Ca 2 +-dependent exocytosis. [3] While SUs exert hypoglycemic action via a direct stimulation of insulin release during short term administration in type 2 diabetic patients, their activity declines during long term applica-tion, which has been suggested to be directly attributable to a desensitization of /-cells to SUs. [4] [5] [6] [7] In vitro chronic exposure of pancreatic islets to SUs is also known to cause impairment of secretory response to subsequent stimulation by glucose or SUs. [8] [9] [10] [11] The mechanisms underlying *Address for correspondence: Metabolic properties of NAT may explain some of the pharmacological differences between those of NAT and those of SUs and REP. [12, 13] MATERIALS AND METHODS receptor/KATp channels; [17] (2) the kinetics of in vitrofin vivo insulinotropic action;[ [18] [19] [20] [21] [22] (3) the glucose-dependence; [23, 24] and (4) the sensitivity to metabolic inhibitors. [25] These findings collectively indicated the uniqueness of NAT action and possibly a distinct receptor/ effector system(s In conclusion, the maintenance of insulinotropic efficacy of NAT in islets desensitized to SUs adds to the list of properties of this agent that distinguish it from other SUR ligands, despite the presumed common basic mechanism of action of said agents.
